| Name | Title | Contact Details |
|---|
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Peppy is the digital health health app that supports menopause, fertility, mens health, womens health and more with real health experts.
Medaudit Services Inc is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MEDO USA is a Roselle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Galileo is a modern medical practice that provides full spectrum medical care, from urgent to chronic, across digital and in-person settings. They bring the best doctors to patients: at home, in the community, and on their mobile device.